. Author manuscript; available in PMC: 2012 Nov 1.

Published in final edited form as: Bioorg Med Chem. 2011 Sep 17;19(21):6167–6173. doi: 10.1016/j.bmc.2011.09.024

Table 1.

Particle size and surface charge of drug-encapsulated combinatorial-designed dextran nanoparticles

Drug	Lipid-Modifed Dextran	Drug LogP	Hydrodynamic Diameter		Zeta Potential (mV)
Drug	Lipid-Modifed Dextran	Drug LogP	Mean Diameter (nm)	Polydispersity Index	Zeta Potential (mV)
Doxorubicin	C2H5	−0.50	295 ± 1.7^*	0.2	−1.21 ± 3.31
Daunorubicin	C2H5	0.10	245 ± 1.5	0.2	−1.33 ± 2.55
Idarubicin	C2H5	0.20	233 ± 1.5	0.2	−1.45 ± 3.22
Topotecan	C2H5	0.80	193 ± 1.3	0.3	−1.35 ± 3.61
Etoposide	C4H9	1.00	137 ± 1.4	0.3	−3.38 ± 3.77
Camptothecin	C6H13	1.74	187 ± 1.6	0.4	−3.68 ± 2.01
Docetaxel	C8H17	2.40	212 ± 1.4	0.2	−3.58 ± 2.23
Paclitaxel	C8H17	3.00	225 ± 1.5	0.2	−4.11 ± 1.89

Mean ± SD, n = 3.